Literature DB >> 3876679

The effect of treatment with Corynebacterium parvum on the development and growth of experimental hematogenic metastases of schwannoma in the rat.

J A Bash, T I Mandybur, W A Ritschel.   

Abstract

Single i.v. administration of Corynebacterium parvum 5 days before i.v. injection of 10(6) tissue cultured syngeneic schwannoma cells in Lewis rats resulted in extension of survival time (P less than 0.05). There was a significant decrease in metastatic tumor incidence for lung, heart, and kidney and decreased lung tumor growth with approximately 50% of the lung tumor burden of untreated controls (P less than 0.05). Rats treated similarly with C. parvum 10 days after tumor cell injection showed no enhanced survival; to the contrary, their survival was shortened. Moreover, tumor incidence in the post-treated group was not significantly different from the control but significantly increased in comparison to the pretreated group. Enhanced lung tumor growth resulted in a final tumor burden about twice that of untreated controls (P less than 0.05).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3876679     DOI: 10.1007/bf00688951

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  16 in total

1.  Mechanisms of antitumor action of Corynebacterium parvum: replicating short-lived T cells as the mediators of potentiated tumor-specific immunity.

Authors:  R L Tuttle; R J North
Journal:  J Reticuloendothel Soc       Date:  1976-09

2.  An experimental model for the treatment of pulmonary metastases.

Authors:  J Shaeffer; A M El-Mahdi; W C Constable
Journal:  Eur J Cancer       Date:  1975-07       Impact factor: 9.162

3.  A role for T lymphocytes in tumour inhibition and enhancement caused by systemic administration of Corynebacterium parvum.

Authors:  L J Peters; W H McBride; K A Mason; L Milas
Journal:  J Reticuloendothel Soc       Date:  1978-07

4.  Suppression of rat T cell proliferation by Corynebacterium parvum: T cell requirement for induction.

Authors:  J A Bash
Journal:  J Reticuloendothel Soc       Date:  1978-01

5.  Suppression of natural killer cell cytotoxicity by splenocytes from Corynebacterium parvum-injected, bone marrow-tolerant, and infant mice.

Authors:  C A Savary; E Lotzová
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

Review 6.  Corynebacterium parvum as an immunotherapeutic anticancer agent.

Authors:  M T Scott
Journal:  Semin Oncol       Date:  1974-12       Impact factor: 4.929

7.  Daily intravenous infusions of Corynebacterium parvum in twenty patients with disseminated cancer: a preliminary report of clinical and biologic findings.

Authors:  L Israël; R Edelstein; A Depierre; N Dimitrov
Journal:  J Natl Cancer Inst       Date:  1975-07       Impact factor: 13.506

8.  An analysis of the factors allowing promotion (rather than inhibition) of tumour growth by Corynebacterium parvum.

Authors:  R Bomford
Journal:  Int J Cancer       Date:  1977-05-15       Impact factor: 7.396

9.  Splenic suppressor macrophages induced in mice by injection of Corynebacterium parvum.

Authors:  H Kirchner; H T Holden
Journal:  J Immunol       Date:  1975-11       Impact factor: 5.422

10.  Immunity to transplantable nitrosourea-induced neurogenic tumors. I. Potentiation of tumor immunity with Corynebacterium parvum.

Authors:  H M Cravioto; E DeBernardo; G M Hochwald; J G Thorbecke
Journal:  J Neuropathol Exp Neurol       Date:  1981-09       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.